We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Gene Therapy Technique Cures Cystic Fibrosis in Culture Model

By LabMedica International staff writers
Posted on 31 Jul 2009
A gene therapy technique based on a parainfluenza virus vector was used to successfully cure an in vitro model of cystic fibrosis.

Cystic fibrosis (CF) lung disease results from reduced airway surface hydration leading to decreased mucus clearance that precipitates bacterial infection and progressive obstructive lung disease. More...
CF is a genetic disease, and the mutant protein is a chloride ion channel (CFTR) that normally regulates ion and fluid transport on the airway surface.

Investigators at the University of North Carolina (Chapel Hill, USA) reasoned that the most appropriate means for delivering a gene to lung tissue was a virus that specialized in invading the lungs. They created an in vitro model of CF by growing cultures of ciliated surface airway epithelium (CF HAE) cells obtained from a CF patient. The cultures were then treated with parainfluenza virus that had been genetically engineered to carry the normal CFTR gene.

Results published in the July 21, 2009, online edition of the journal PLoS Biology revealed that the vector delivered CFTR to more than 60% of airway surface epithelial cells, and the expression of CFTR protein in the CF HAE cells was approximately 100-fold higher than endogenous levels found in normal HAE cells.

By titering the amount of CFTR gene in the vector, the investigators were able to determine that uptake of the gene by 25% of the cells was sufficient to restore normal function to the entire culture.

"We discovered that if you take a virus that has evolved to infect the human airways, and you engineer a normal CFTR gene into it, you can use this virus to correct all of the hallmark CF features in the model system that we used,” said senior author Dr. Raymond J. Pickles, associate professor of microbiology and immunology at the University of North Carolina. "This is the first demonstration in which we have been able to execute delivery in an efficient manner. When you consider that in past gene therapy studies, the targeting efficiency has been somewhere around 0.1% of cells, you can see this is a giant leap forward.”

"We have not generated a vector that we can go out and give to patients now,” said Dr. Pickles, "but these studies continue to convince us that a gene replacement therapy for CF patients will some day be available in the future.”

Related Links:
University of North Carolina



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.